Ramon Güimil García

Chief Tech/Sci/R&D Officer at Hummingbird Diagnostics GmbH

Health Technology

Consumer Services

Profile

Ramon Güimil García is currently working as Vice President-Research & Development at Hummingbird Diagnostics GmbH.
Prior to this, he worked as Principal at The European Molecular Biology Laboratory and Nucleic Acid Synthesis Group.

Ramon Güimil García active positions

Companies	Position	Start
Hummingbird Diagnostics GmbH Hummingbird Diagnostics GmbH Medical SpecialtiesHealth Technology Hummingbird Diagnostics GmbH specializes in patient-friendly diagnostics for early disease detection, personalized medicine, and lifetime health monitoring. Hummingbird Diagnostics is based in Heidelberg, DE and was founded by Jochen Kohlhaas and Karoly Nikolich. The German company uses liquid biopsies based on miRNA biomarkers to detect diseases such as lung cancer, melanoma, breast cancer, multiple sclerosis, Alzheimer's, Parkinson's, heart diseases, and IBD. Jochen Kohlhaas has been the CEO since incorporation.	Chief Tech/Sci/R&D Officer	29/11/2009

All active positions of Ramon Güimil García

Former positions of Ramon Güimil García

Companies	Position	End
The European Molecular Biology Laboratory	Corporate Officer/Principal	-
Nucleic Acid Synthesis Group	Corporate Officer/Principal	-

See the detail of Ramon Güimil García's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Ramon Güimil García's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Hummingbird Diagnostics GmbH Hummingbird Diagnostics GmbH Medical SpecialtiesHealth Technology Hummingbird Diagnostics GmbH specializes in patient-friendly diagnostics for early disease detection, personalized medicine, and lifetime health monitoring. Hummingbird Diagnostics is based in Heidelberg, DE and was founded by Jochen Kohlhaas and Karoly Nikolich. The German company uses liquid biopsies based on miRNA biomarkers to detect diseases such as lung cancer, melanoma, breast cancer, multiple sclerosis, Alzheimer's, Parkinson's, heart diseases, and IBD. Jochen Kohlhaas has been the CEO since incorporation.	Health Technology
Nucleic Acid Synthesis Group